Global Information
회사소개 | 문의 | 비교리스트

개방각녹내장(OAG) : 시장 인사이트, 역학, 시장 예측(-2030년)

Open-Angle Glaucoma - Market Insight, Epidemiology and Market Forecast -2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 04월 상품 코드 780420
페이지 정보 영문 150 Pages
가격
US $ 6,950 ₩ 8,638,000 PDF by E-mail (Single User License)
US $ 13,900 ₩ 17,276,000 PDF by E-mail (Site License)
US $ 20,850 ₩ 25,914,000 PDF by E-mail (Global License)


개방각녹내장(OAG) : 시장 인사이트, 역학, 시장 예측(-2030년) Open-Angle Glaucoma - Market Insight, Epidemiology and Market Forecast -2030
발행일 : 2020년 04월 페이지 정보 : 영문 150 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 개방각녹내장(OAG) 시장을 조사했으며, 질병 개요 및 현행 치료법, 출시 치료제 및 신약의 개요, 전체 및 각국의 시장 동향, 역학적 예측, 시장 규모, 유병 수·이환 수의 추이와 예측, 미충족 요구, 시장 성장요인 및 장벽 등을 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 개방각녹내장(OAG) 시장의 개요

  • 개방각녹내장(OAG)의 시장 점유율(실적)
  • 개방각녹내장(OAG)의 시장 점유율(예측)

제3장 질병 배경과 개요 : 개방각녹내장(OAG)

  • 서론
  • 분류
  • 징후와 증상
  • 위험인자
  • 임상 증상
  • 유전적 기반
    • 마이오실린(MYOC, OMIM #601652)
    • 옵티뉴린(OPTN, OMIM #602432)
    • TANK 결합 키나아제-1(TANK-binding Kinase-1)
    • WD 리피트 36(WDR36, OMIM 609669)
  • 진단

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 주요 7개국 녹내장의 총유병 수
  • 주요 7개국 개방각녹내장(OAG)의 총유병 수

제5장 미국 개방각녹내장(OAG)의 역학

  • 가정과 이론적 근거
  • 개방각녹내장(OAG)의 유병 수
  • 개방각녹내장(OAG)의 유병 수 : 성별
  • 개방각녹내장(OAG)의 유병 수 : 연령별
  • 개방각녹내장(OAG)의 유병 수 : 병형별

제6장 EU 5개국 개방각녹내장(OAG)의 역학

  • 가정과 이론적 근거
  • 독일
    • 가정과 이론적 근거
    • 개방각녹내장(OAG)의 유병 수
    • 개방각녹내장(OAG)의 유병 수 : 성별
    • 개방각녹내장(OAG)의 유병 수 : 연령별
    • 개방각녹내장(OAG)의 유병 수 : 병형별
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제7장 일본 개방각녹내장(OAG)의 역학

  • 가정과 이론적 근거
  • 개방각녹내장(OAG)의 유병 수
  • 개방각녹내장(OAG)의 유병 수 : 성별
  • 개방각녹내장(OAG)의 유병 수 : 연령별
  • 개방각녹내장(OAG)의 유병 수 : 병형별

제8장 치료 알고리즘·현행 치료

  • 치료 알고리즘
  • 치료와 관리
    • 치료의 기초
    • 치료 옵션
    • 투약 치료
    • 레이저육주성형술
    • 외과적 치료
  • 중증 또는 불가역적 시력 상실 환자의 관리

제9장 미충족 요구

제10장 출시 치료제

  • 출시 치료제와 치료 분류
  • ROCKLATAN : Aerie Pharmaceuticals
    • 의약품 개요
    • 규제 마일스톤
    • 임상 동향
    • 안전성과 유효성
    • 제품 개요
  • Rhopressa : Aerie Pharmaceuticals
  • XELPROS(latanoprost ophthalmic emulsion) 0.005% : Sun Pharma Advanced Research Company Limited
  • EYBELIS Ophthalmic Solution 0.002% : Santen Pharmaceutical/Ube Industries
  • VYZULTA: Bausch and Lomb
  • TAPCOM(DE-111) : Santen Pharmaceutical Co., Ltd.
  • GLANATEC : D.Western Therapeutics Institute(DWTI)/Kowa LTD.
  • SIMBRINZA(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research
  • ZIOPTAN(tafluprost): Merck Sharp & Dohme Corp.
  • DuoTrav PQ(travoprost/timolol): Novartis/Alcon Research
  • TRAVATAN Z(travoprost ophthalmic solution) 0.004% : Alcon Research, a Novartis company
  • LUMIGAN 0.01%(bimatoprost ophthalmic solution): Allergan

제11장 신약

  • 키 크로스 경쟁
  • Bimatoprost SR(Sustained-Release) : Allergan
    • 의약품 개요
    • 규제 마일스톤
    • 임상 동향
    • 안전성과 유효성
    • 제품 개요
  • PDP-716 : Sun Pharma Advanced Research Company Limited(SPARC)
  • PRO-12 : Laboratorios Sophia S.A de C.V.
  • Brinzolamide Ophthalmic Suspension 1% : Perrigo Company
  • Trabodenoson : Inoteck
  • DE-130A(latanoprost) : Santen Pharmaceutical
  • CKD-351 : Chong Kun Dang Pharmaceutical
  • OTX-TP(Travoprost) : Ocular Therapeutix
  • Sepetaprost(DE-126/ONO-9054) : Santen Inc./Ono Pharmaceutical

제12장 개방각녹내장(OAG) : 주요 7개국 시장 분석

  • 주요 조사 결과
  • 주요 7개국의 시장 규모
  • 주요 7개국의 시장 규모 : 치료제별

제13장 미국의 개방각녹내장(OAG) 시장 전망

  • 시장 규모
  • 시장 규모 : 치료제별

제14장 EU 5개국의 개방각녹내장(OAG) 시장 전망

  • 독일
    • 시장 규모
    • 시장 규모 : 치료제별
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제15장 일본의 개방각녹내장(OAG) 시장 전망

  • 시장 규모
  • 시장 규모 : 치료제별

제16장 시장 성장요인

제17장 시장 장벽

제18장 부록

제19장 DelveInsight의 서비스 내용

제20장 면책사항

제21장 DelveInsight 소개

KSA 19.11.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 Summary of OAG Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Clinical Stages of Primary Open-Angle Glaucoma
  • Table 3 Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
  • Table 4 Genes associated with the risk of POAG
  • Table 5 Innate and adaptive immunity changes in POAG
  • Table 6 The definitions and levels of evidence to rate individual studies
  • Table 7 Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE
  • Table 8 Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
  • Table 9 Total Prevalence of Glaucoma in the 7MM (2017-2030)
  • Table 10 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Table 11 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Table 12 Total Prevalence of Glaucoma in the United States (2017-2030)
  • Table 13 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2030)
  • Table 14 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2030)
  • Table 15 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States(2017-2030)
  • Table 16 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2030)
  • Table 17 Total Prevalence of Glaucoma in Germany (2017-2030)
  • Table 18 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 19 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 20 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 21 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 22 Total Prevalence of Glaucoma in France (2017-2030)
  • Table 23 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2030)
  • Table 24 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 25 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 26 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 27 Total Prevalence of Glaucoma in Italy (2017-2030)
  • Table 28 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 29 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 30 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 31 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 32 Total Prevalence of Glaucoma in Spain (2017-2030)
  • Table 33 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 34 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 35 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 36 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 37 Total Prevalence of Glaucoma in the United Kingdom (2017-2030)
  • Table 38 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 39 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 40 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 41 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 42 Total Prevalence of Glaucoma in Japan (2017-2030)
  • Table 43 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 44 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 45 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 46 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 47 Suggestions for the Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension
  • Table 48 Pharmacological Agents for Management of Primary Open-Angle Glaucoma
  • Table 49 General Guidelines for Postoperative Management of Patients Following Argon Laser Trabeculoplasty
  • Table 50 European Glaucoma Society Terminology and Guidelines for Glaucoma
  • Table 51 List of Marketed Drugs and their Relative Therapeutic Classes
  • Table 52 Rocklatan, Clinical Trial Description, 2020
  • Table 53 Rhopressa, Clinical Trial Description, 2020
  • Table 54 EYBELIS Ophthalmic Solution 0.002%, Clinical Trial Description, 2020
  • Table 55 Vyzulta, Clinical Trial Description, 2020
  • Table 56 DE-111; Clinical Trial Description, 2020
  • Table 57 Glanatec, Clinical Trial Description, 2020
  • Table 58 Simbrinza, Clinical Trial Description, 2020
  • Table 59 Zioptan, Clinical Trial Description, 2020
  • Table 60 DuoTrav, Clinical Trial Description, 2020
  • Table 61 TRAVATAN Z, Clinical Trial Description, 2020
  • Table 62 Lumigan 0.01%, Clinical Trial Description, 2020
  • Table 63 Emerging Keycross Competition
  • Table 64 Bimatoprost SR (Sustained-Release) Clinical Trial Description, 2020
  • Table 65 PDP - 716, Clinical Trial Description, 2020
  • Table 66 PRO-122, Clinical Trial Description, 2020
  • Table 67 Brinzolamide Ophthalmic Suspension 1%, Clinical Trial Description, 2020
  • Table 68 DE-130A (latanoprost), Clinical Trial Description, 2020
  • Table 69 CKD-351, Clinical Trial Description, 2020
  • Table 70 DE-126, Clinical Trial Description, 2020
  • Table 71 NCX 470, Clinical Trial Description, 2020
  • Table 72 SYL040012 (bamosiran) , Clinical Trial Description, 2020
  • Table 73 ENV515 Travoprost XR, Clinical Trial Description, 2020
  • Table 74 Nyxol (Phentolamine Mesylate), Clinical Trial Description, 2020
  • Table 75 POLAT-001, Clinical Trial Description, 2020
  • Table 76 Trabodenoson (INO-8875), Clinical Trial Description, 2020
  • Table 77 OTX-TP (Travoprost), Clinical Trial Description, 2020
  • Table 78 Market Size of Open-Angle Glaucoma in 7MM in USD Million (2017-2030)
  • Table 79 Market Size of Open-Angle Glaucoma by therapies in the 7MM, in USD Million (2017-2030)
  • Table 80 Currently Prescribed Classes and their Side-Effects
  • Table 81 The US Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 82 Market Size of Open-Angle Glaucoma by therapies in the US, in USD Million (2017-2030)
  • Table 83 Germany Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 84 Market Size of Open-Angle Glaucoma by therapies in Germany, in USD Million (2017-2030)
  • Table 85 France Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 86 Market Size of Open-Angle Glaucoma by therapies in France, in USD Million (2017-2030)
  • Table 87 Italy Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 88 Market Size of Open-Angle Glaucoma by therapies in Italy, in USD Million (2017-2030)
  • Table 89 Spain Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 90 Market Size of Open-Angle Glaucoma by therapies in Spain, in USD Million (2017-2030)
  • Table 91 The UK Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 92 Market Size of Open-Angle Glaucoma by therapies in the UK, in USD Million (2017-2030)
  • Table 93 Japan Market Size of Open-Angle Glaucoma in USD Million (2017-2030)
  • Table 94 Market Size of Open-Angle Glaucoma by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1 Aqueous humor production and flow
  • Figure 2 Development of Glaucoma
  • Figure 3 Classification of Open-Angle Glaucoma
  • Figure 4 Symptoms of Open-Angle Glaucoma
  • Figure 5 Risk Factors Associated with POAG
  • Figure 6 Factors Contributing to the Pathophysiology of Glaucomatous Neurodegeneration
  • Figure 7 Pathophysiology of Primary Open-Angle Glaucoma
  • Figure 8 Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by a MYOC mutation
  • Figure 9 Diagnosis of Primary Open-Angle Glaucoma (POAG)
  • Figure 10 Glaucoma Assessment (Optic Nerve)
  • Figure 11 Total Prevalence of Glaucoma in the 7MM (2017-2030)
  • Figure 12 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Figure 13 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Figure 14 Total Prevalence of Glaucoma in the United States (2017-2030)
  • Figure 15 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2030)
  • Figure 16 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2030)
  • Figure 17 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2030)
  • Figure 18 Type-Specific Diagnosed Prevalence of OAG in the United States (2017-2030)
  • Figure 19 Total Prevalence of Glaucoma in Germany (2017-2030)
  • Figure 20 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 21 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 22 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 23 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 24 Total Prevalence of Glaucoma in France (2017-2030)
  • Figure 25 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2030)
  • Figure 26 Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 27 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 28 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 29 Total Prevalence of Glaucoma in Italy (2017-2030)
  • Figure 30 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 31 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 32 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 33 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 34 Total Prevalence of Glaucoma in Spain (2017-2030)
  • Figure 35 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 36 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 37 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 38 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 39 Total Prevalence of Glaucoma in the United Kingdom (2017-2030)
  • Figure 40 Total Diagnosed Prevalent Population of OAG in the United Kingdom (2017-2030)
  • Figure 41 Gender-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 42 Age-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 43 Type-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 44 Total Prevalence of Glaucoma in Japan (2017-2030)
  • Figure 45 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 46 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 47 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 48 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 49 Treatment of primary open-angle glaucoma: Medical treatment
  • Figure 50 Treatment Algorithm for Open-Angle Glaucoma
  • Figure 51 Unmet Needs of Open-Angle Glaucoma
  • Figure 52 Factors which can influence Patients Quality of Life (QoL)
  • Figure 53 Market Size of Open-Angle Glaucoma in the 7MM in USD Million (2017-2030)
  • Figure 54 Market Size of Open-Angle Glaucoma by therapies in the 7MM, in USD Million (2017-2030)
  • Figure 55 Market Size of Open-Angle Glaucoma in the US, USD Millions (2017-2030)
  • Figure 56 Market Size of Open-Angle Glaucoma by therapies in the United States, in USD Million (2017-2030)
  • Figure 57 Market Size of Open-Angle Glaucoma in Germany, USD Millions (2017-2030)
  • Figure 58 Market Size of Open-Angle Glaucoma by therapies in Germany, in USD Million (2017-2030)
  • Figure 59 Market Size of Open-Angle Glaucoma in France, USD Millions (2017-2030)
  • Figure 60 Market Size of Open-Angle Glaucoma by therapies in France, in USD Million (2017-2030)
  • Figure 61 Market Size of Open-Angle Glaucoma in Italy, USD Millions (2017-2030)
  • Figure 62 Market Size of Open-Angle Glaucoma by therapies in Italy in USD Million (2017-2030)
  • Figure 63 Market Size of Open-Angle Glaucoma in Spain, USD Millions (2017-2030)
  • Figure 64 Market Size of Open-Angle Glaucoma by therapies in Spain in USD Million (2017-2030)
  • Figure 65 Market Size of Open-Angle Glaucoma in the UK, USD Millions (2017-2030)
  • Figure 66 Market Size of Open-Angle Glaucoma by therapies in the UK in USD Million (2017-2030)
  • Figure 67 Market Size of Open-Angle Glaucoma in Japan, USD Millions (2017-2030)
  • Figure 68 Market Size of Open-Angle Glaucoma by therapies in Japan in USD Million (2017-2030)
  • Figure 69 Market Drivers
  • Figure 70 Market Barriers
  • Figure 71 SWOT analysis

DelveInsight's Open-angle glaucoma (OAG) - Market Insights, Epidemiology, and Market Forecast-2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. The current treatment management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Open-angle glaucoma - Disease Understanding and Treatment Algorithm

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases.

OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of OAG are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

Open-angle glaucoma - Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. DelveInsight's analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this, it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG.

Open-angle glaucoma - Drug Chapters

This segment of the Open-angle glaucoma (OAG) report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment and market of OAG are dependent on the class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP - 716 (Sun Pharma), Trabodenoson (Inotek Pharmaceuticals), DE-30A (Santen), and others.

Prostaglandin derivatives, beta-blockers, Topical carbonic anhydrase inhibitors (CAIs), alpha2-adrenergic receptor agonists and Combination therapies are the most preferred classes for the treatment of open-angle glaucoma. In the United States, drugs of this class have been approved in the past few years like Vyzulta, Xelpros, Travatan Z, and a few others by the US FDA. Rhopressa which is marketed in both the US and Europe (Rhokiinsa), has recently completed the phase II trial in Japan. The company is looking to meet with Japan's Pharmaceutical and Medical Devices Agency to discuss these results and identify the next steps for a phase III program in Japan. Apart from this, Ube Industries and Santen Pharmaceutical in Japan developed a famous ophthalmic product known as Omidenepag isopropyl ophthalmic solution 0.002 %, which is marketed under the name of EYBELIS is a selective prostaglandin E2 receptor 2 agonist with a non-prostaglandin structure for the treatment of glaucoma and ocular hypertension.

There are several unmet needs in the management of Glaucoma and to meet these unmet needs, various pharmaceutical companies have started working toward the development of the novel product for this indication. Pharmaceutical companies, like Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia S.A de C.V., Nicox Ophthalmics, and Nicox Ophthalmics developing products that have the potential to change the open-angle glaucoma treatment landscape.

Allergan's drug candidate, Bimatoprost SR is a biodegradable sustained-release implant, which is currently under development in phase III for the treatment of OAG and ocular hypertension. The solid, rod-shaped implant consists of the prostaglandin analog (PGA) bimatoprost within the company's Novadur platform for drug delivery. In July 2019, the United States Food and Drug Administration (US FDA) accepted Allergan's new drug application for bimatoprost sustained-release in patients with OAG or ocular hypertension. The FDA is expected to take action on the NDA by the end of the first half of 2020.

PDP - 716 is the once-a-day formulation of Brimonidine developed using SPARC's TearActTM Technology for treatment of Glaucoma by Sun Pharma. PDP - 716 provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. SPARC initiated the pivotal Phase III study for PDP - 716 in the USA. The study is randomizing patients and is expected to be completed by Q4 FY 2020. SPARC is in discussion with potential partners for licensing of PDP - 716.

Among all these mentioned companies Santen is constantly working to meet the unmet needs of the OAG. Two of its products are in pipeline (phase II and Phase III), i.e., DE-130A and Sepetaprost (ONO-9054). DE-130A is an ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension. This product is in phase III clinical development stage. Santen recently initiated the phase III trial in Europe and Asia and planning to complete it in 2021. On the other hand, ONO-9054 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). ONO-9054 is expected to show a superior intraocular pressure (IOP) lowering effect compared to FP receptor agonists.

The company has completed the Phase II clinical trial of ONO-9054 for the treatment of glaucoma and ocular hypertension in the US. In the future, Santen will seek manufacturing and marketing approval for ONO-9054 on a worldwide basis. There are several other products in the clinical development for the treatment of OAG.

Open-angle glaucoma - Market Outlook

The Open-angle glaucoma (OAG) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

As per the assessment by DelveInsight's analysts, it has been observed that the market size of OAG was observed to be USD 3,316.71 million in 2017, in the 7MM. Among all the seven major markets, the United States covers the major market share that accounts for 41.01% of the 7MM. In 2017, the market size was accessed to be USD 1,360.30 million in the country.

The products which are anticipated to be launched in the 7MM include Bimatoprost SR (Sustained-Release; Allergan), DE-117 (omidenepag isopropyl; Santen Pharmaceutical); PRO-122 (Laboratorios Sophia); PDP - 716 (Brimonidine; Sun Pharma); Sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics) and Nyxol (Phentolamine Mesylate: Ocuphire Pharma). However, in addition to this, it is anticipated that Aerie Pharma with its two products ROCKLATAN and RHOPRESSA/Rhokiinsa will definitely show an impact on the open-angle glaucoma market of Europe. Recently, in November 2019, the European Commission (EC) granted marketing authorization to Rhokiinsa 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.

Besides this Sun Pharma Advanced Research Company (SPARC) is also expecting the launch of its product PDP - 716 (Brimonidine). In addition to this, a product named), DE-130A (of Santen Pharmaceutical is also anticipated to be launched in the European countries. ROCKLATAN and RHOPRESSA are approved in the US and recently Aerie pharma received a positive opinion from the CHMP. This positive opinion will help in the smooth launch of RHOPRESSA (under the name RHOKIINSA).

Some of these products have completed the late clinical stages of development, while others are in ongoing late clinical development stages. These drug candidates have shown very promising results and it has been anticipated by DelveInsight's analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of OAG will have better management practices.

Open-angle glaucoma (OAG) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

The current therapeutic landscape of advanced stage OAG in the 7MM is driven by several approved therapies, including those with generic products. Of this, majority of the market share is accommodated by Prostaglandin analogs generating USD 1,806.12 million, followed by Carbonic anhydrase inhibitors generating USD 578.42 million while Miotics contributed the least towards the market share, with USD 146.31 million.

To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of OAG during our forecast period, including In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP - 716 (Sun Pharma.), DE-130A (Santen), and others.

Open-angle glaucoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Open-angle glaucoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Countries Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Open-angle glaucoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Open-angle glaucoma market
  • Organize sales and marketing efforts by identifying the best opportunities for Open-angle glaucoma market
  • To understand the future market competition in the Open-angle glaucoma market.

Table of Contents

1. Key Insights

2. Executive Summary of Open-Angle Glaucoma

3. Open-Angle Glaucoma (OAG): Market Overview at a Glance

  • 3.1. Total Market Share (%) Distribution of OAG in 2017
  • 3.2. Total Market Share (%) Distribution of OAG in 2030

4. Open-Angle Glaucoma: Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Classification of Open-Angle Glaucoma
  • 4.3. Signs and Symptoms of Open-Angle Glaucoma
  • 4.4. Risk Factors of Primary Open-Angle Glaucoma (POAG)
    • 4.4.1. General
    • 4.4.2. Ocular
    • 4.4.3. Nonocular
    • 4.4.4. Ocular Hypertension
  • 4.5. Pathophysiology of Primary Open-Angle Glaucoma (POAG)
  • 4.6. Genes Involved in Primary Open-Angle Glaucoma
    • 4.6.1. Myocilin
    • 4.6.2. Optineurin
    • 4.6.3. TANK-binding Kinase-1 (TBK1)
    • 4.6.4. WD-repeat domain 36 (WDR36, OMIM 609669)
  • 4.7. Biomarkers associated with Primary Open Angle Glaucoma (POAG)
  • 4.8. Diagnosis of Open-Angle Glaucoma
    • 4.8.1. Diagnosis of Primary Open-Angle Glaucoma
    • 4.8.2. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

5. Case Reports

  • 5.1. Managing Juvenile Open-Angle Glaucoma
  • 5.2. Visual improvement following glaucoma surgery: a case report
  • 5.3. Evidence-based medicine in glaucoma surgery

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Epidemiology and Market Methodology
  • 6.3. Total Prevalence of Glaucoma in the 7MM
  • 6.4. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM
  • 6.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalence of Glaucoma in the United States
  • 7.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States
  • 7.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 7.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 7.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8. EU5 Epidemiology

  • 8.1. Germany Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Total Prevalence of Glaucoma in Germany
    • 8.1.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany
    • 8.1.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 8.1.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 8.1.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
  • 8.2. France Epidemiology
    • 8.2.1. Assumptions and rationale
    • 8.2.2. Total Prevalence of Glaucoma in France
    • 8.2.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France
    • 8.2.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 8.2.5. Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 8.2.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
  • 8.3. Italy Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Total Prevalence of Glaucoma in Italy
    • 8.3.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy
    • 8.3.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 8.3.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 8.3.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
  • 8.4. Spain Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Total Prevalence of Glaucoma in Spain
    • 8.4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain
    • 8.4.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 8.4.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 8.4.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
  • 8.5. United Kingdom Epidemiology
    • 8.5.1. Assumptions and Rationale
    • 8.5.2. Total Prevalence of Glaucoma in the United Kingdom
    • 8.5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom
    • 8.5.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 8.5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 8.5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Total Prevalence of Glaucoma in Japan
  • 9.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan
  • 9.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
  • 9.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
  • 9.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices

  • 10.1. Treatment Algorithm for Open-Angle Glaucoma
  • 10.2. Treatment and Management for Open-Angle Glaucoma
    • 10.2.1. Basis for Treatment
    • 10.2.2. Available Treatment Options
    • 10.2.3. Medical (Pharmaceutical) Treatment
    • 10.2.4. Laser Trabeculoplasty
    • 10.2.5. Surgery
  • 10.3. Treatment Guidelines
    • 10.3.1. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
    • 10.3.2. European Glaucoma Society Terminology and Guidelines for Glaucoma
  • 10.4. Prognosis and Follow-up of Open-Angle Glaucoma
    • 10.4.1. Prognosis
    • 10.4.2. Frequency of Follow-up
    • 10.4.3. Therapy Modification
    • 10.4.4. Effectiveness of Treatment
  • 10.5. Management of Patients with Severe, Irreversible Vision Loss

11. Unmet Needs

12. Marketed Products

  • 12.1. Marketed Products And Their Relative Therapeutic Classes
  • 12.2. Rocklatan: Aerie Pharmaceuticals
    • 12.2.1. Product Description
    • 12.2.2. Regulatory Milestones
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and efficacy
    • 12.2.5. Adverse Reaction
    • 12.2.6. Product Profile
  • 12.3. Rhopressa: Aerie Pharmaceuticals
    • 12.3.1. Product Description
    • 12.3.2. Regulatory Milestones
    • 12.3.3. Clinical Development
    • 12.3.4. Safety and efficacy
    • 12.3.5. Product Profile
  • 12.4. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited
    • 12.4.1. Product Description
    • 12.4.2. Regulatory Milestones
    • 12.4.3. Clinical Development
    • 12.4.4. Product Profile
  • 12.5. EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries
    • 12.5.1. Product Description
    • 12.5.2. Regulatory Milestones
    • 12.5.3. Clinical Development
    • 12.5.4. Safety and efficacy
    • 12.5.5. Product Profile
  • 12.6. VYZULTA: Bausch and Lomb
    • 12.6.1. Product Description
    • 12.6.2. Regulatory Milestones
    • 12.6.3. Clinical Development
    • 12.6.4. Safety and efficacy
    • 12.6.5. Product Profile
  • 12.7. TAPCOM/ DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.
    • 12.7.1. Product Description
    • 12.7.2. Regulatory Milestones
    • 12.7.3. Clinical Development
    • 12.7.4. Product Profile
  • 12.8. GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa LTD.
    • 12.8.1. Product Description
    • 12.8.2. Regulatory Milestones
    • 12.8.3. Clinical Development
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research
    • 12.9.1. Product Description
    • 12.9.2. Regulatory Milestones
    • 12.9.3. Clinical Development
    • 12.9.4. Safety and efficacy
    • 12.9.5. Product Profile
  • 12.10. ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.
    • 12.10.1. Product Description
    • 12.10.2. Regulatory Milestones
    • 12.10.3. Clinical Development
    • 12.10.4. Safety and efficacy
    • 12.10.5. Product Profile
  • 12.11. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
    • 12.11.1. Product Description
    • 12.11.2. Regulatory Milestones
    • 12.11.3. Clinical Development
    • 12.11.4. Safety and efficacy
    • 12.11.5. Product Profile
  • 12.12. TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company
    • 12.12.1. Product Description
    • 12.12.2. Regulatory Milestones
    • 12.12.3. Clinical Development
    • 12.12.4. Safety and efficacy
    • 12.12.5. Product Profile
  • 12.13. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan
    • 12.13.1. Product Description
    • 12.13.2. Regulatory Milestones
    • 12.13.3. Clinical Development
    • 12.13.4. Product Profile

13. Emerging Therapies

  • 13.1. Key Cross Competition
  • 13.2. Bimatoprost SR (Sustained-Release): Allergan
    • 13.2.1. Product Description
    • 13.2.2. Other Developmental Activities
    • 13.2.3. Clinical Development
    • 13.2.4. Safety and Efficacy
    • 13.2.5. Product Profile
  • 13.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
    • 13.3.1. Product Description
    • 13.3.2. Other Developmental Activities
    • 13.3.3. Clinical Development
    • 13.3.4. Safety and Efficacy
    • 13.3.5. Product Profile
  • 13.4. PRO-122: Laboratorios Sophia S.A de C.V.
    • 13.4.1. Product Description
    • 13.4.2. Clinical Development
    • 13.4.3. Safety and Efficacy
    • 13.4.4. Product Profile
  • 13.5. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company
    • 13.5.1. Product Description
    • 13.5.2. Clinical Development
    • 13.5.3. Product Profile
  • 13.6. DE-130A (latanoprost): Santen Pharmaceutical
    • 13.6.1. Product Description
    • 13.6.2. Clinical Development
    • 13.6.3. Product Profile
  • 13.7. CKD-351: Chong Kun Dang Pharmaceutical
    • 13.7.1. Product Description
    • 13.7.2. Other Developmental Activities
    • 13.7.3. Clinical Development
    • 13.7.4. Product Profile
  • 13.8. Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical
    • 13.8.1. Product Description
    • 13.8.2. Other Development Activities
    • 13.8.3. Clinical Development
    • 13.8.4. Product Profile
  • 13.9. NCX 470: Nicox Ophthalmics
    • 13.9.1. Product Description
    • 13.9.2. Other Developmental Activities
    • 13.9.3. Clinical Development
    • 13.9.4. Product Profile
  • 13.10. Bamosiran (SYL040012): Sylentis
    • 13.10.1. Product Description
    • 13.10.2. Other Developmental Activities
    • 13.10.3. Clinical Development
    • 13.10.4. Product Profile
  • 13.11. ENV515 (Travoprost XR): Envisia Therapeutics
    • 13.11.1. Product Description
    • 13.11.2. Other Developmental Activities
    • 13.11.3. Clinical Development
    • 13.11.4. Product Profile
  • 13.12. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
    • 13.12.1. Product Description
    • 13.12.2. Other Developmental Activities
    • 13.12.3. Clinical Development
    • 13.12.4. Product Profile
  • 13.13. POLAT-001: Peregrine Ophthalmic
    • 13.13.1. Product Description
    • 13.13.2. Other Developmental Activities
    • 13.13.3. Clinical Development
    • 13.13.4. Product Profile

14. Failed Therapies

  • 14.1. Trabodenoson: Inotek Pharmaceuticals
    • 14.1.1. Product Description
    • 14.1.2. Other Developmental Activities
    • 14.1.3. Clinical Development
    • 14.1.4. Safety and Efficacy
    • 14.1.5. Product Profile
  • 14.2. OTX-TP (Travoprost): Ocular Therapeutix
    • 14.2.1. Product Description
    • 14.2.2. Other Developmental Activities
    • 14.2.3. Clinical Development
    • 14.2.4. Product Profile

15. Open-Angle Glaucoma (OAG): 7MM Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Size of Open-Angle Glaucoma in 7MM
  • 15.3. Market Size of Open-Angle Glaucoma by Therapies in the 7MM

16. United States: Market Outlook

  • 16.1. United States Market Size
    • 16.1.1. Total Market size of Open-Angle Glaucoma in the United States
    • 16.1.2. Market Size of Open-Angle Glaucoma by Therapies in the US

17. EU-5 countries: Market Outlook

  • 17.1. Germany Market Size
    • 17.1.1. Total Market size of Open-Angle Glaucoma in Germany
    • 17.1.2. Market Size of Open-Angle Glaucoma by therapies in Germany
  • 17.2. France Market Size
    • 17.2.1. Total Market size of Open-Angle Glaucoma in France
    • 17.2.2. Market Size of Open-Angle Glaucoma by therapies in France
  • 17.3. Italy Market Size
    • 17.3.1. Total Market size of Open-Angle Glaucoma in Italy
    • 17.3.2. Market Size of Open-Angle Glaucoma by therapies in Italy
  • 17.4. Spain Market Size
    • 17.4.1. Total Market size of Open-Angle Glaucoma in Spain
    • 17.4.2. Market Size of Open-Angle Glaucoma by therapies in Spain
  • 17.5. United Kingdom Market Size
    • 17.5.1. Total Market size of Open-Angle Glaucoma in the United Kingdom
    • 17.5.2. Market Size of Open-Angle Glaucoma by therapies in the UK

18. Japan Market Outlook

  • 18.1. Japan Market Size
    • 18.1.1. Total Market size of Open-Angle Glaucoma in Japan
    • 18.1.2. Market Size of Open-Angle Glaucoma by therapies in Japan

19. Access and Reimbursement Overview of Open-Angle Glaucoma

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Appendix

  • 23.1. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

Back to Top
전화 문의
F A Q